Clinical

Dataset Information

0

Safety and efficacy of preoperative chemotherapy with mFOLFOX6+Bevacizumab in patients with liver-only metastases (H2, H3) from colorectal cancer; histological assessment of liver damage from preoperative chemotherapy.


ABSTRACT: Interventions: mFOLFOX6+Bevacizumab was administered for six cycles, but sixth cycle of therapy did not include Bevacizumab. Surgery was planned 2 weeks after the last dose of chemotherapy, resulting in a gap of 6-9 weeks between surgery and the last Bevacizumab dose. Primary outcome(s): Liver resection rate Study Design: Single arm Non-randomized

DISEASE(S): Patients With Liver-only Metastases From Colorectal Cancer

PROVIDER: 2616801 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| S-EPMC7057917 | biostudies-literature
| S-EPMC8682940 | biostudies-literature
2024-06-03 | MSV000094925 | GNPS
2017-09-01 | GSE87455 | GEO
| 2619239 | ecrin-mdr-crc
2024-07-01 | GSE207460 | GEO
2024-07-02 | GSE253735 | GEO
| S-EPMC6373283 | biostudies-literature
| S-EPMC7513559 | biostudies-literature
2017-06-30 | E-MTAB-4439 | biostudies-arrayexpress